1.66; 95% CI 1.03–2.69). These treatment effects are consistent with prior research (24). For individuals who relapsed during the 6-month follow-up period, the average for time to first cigarette was 45.2 days (SD = 50.5) in the bupropion group and 28.2 days (SD = 38.9) in the placebo group (P = 0.0016). At target quit data (TQD), the bupropion group had higher mean withdrawal symptoms (32.3, SD = 7.2) compared with the placebo group (30.7, SD = 7.3) (P = 0.04). Of our original 1295 candidate gene SNPs, 97 (7.5%) were excluded from further analysis after genotyping because they were monomorphic or had low (< 0.01) minor allele frequencies in our samples. The remaining 1198 SNPs had an r2 of 0.8 or greater with 85% of all the common (>0.05%) SNPs within the 58 candidate genes in the current version of HapMap (Genome Build 36, Table 2) (see Supplementary Material, Table S3 for information regarding all the SNPs).
